Should I Buy RCKT? RCKT 2026 Analysis

Should You Buy Rocket Pharmaceuticals Inc (RCKT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.160

1 Day change

5.33%

52 Week Range

11.110

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RCKT is not a good buy right now. The stock is in a clear downtrend (bearish moving averages and weakening MACD), sentiment is pressured by recent analyst downgrades/price-target cuts and stated program risk (Danon), and options flow is skewed bearish on volume. For an impatient investor who doesn’t want to wait for an optimal entry, this setup does not justify buying at current levels.

Technical Analysis

Price/Trend: Strong bearish trend with SMA_200 > SMA_20 > SMA_5, indicating persistent downside momentum across short-, medium-, and long-term timeframes. Momentum: MACD histogram at -0.0434 is below zero and negatively expanding, suggesting downside momentum is still building rather than stabilizing. RSI: RSI_6 at ~25 is oversold, which can support a short-lived bounce, but oversold readings can persist in strong downtrends—so it’s not a reliable buy trigger here. Levels: Pivot 3.645 (overhead), resistance at R1 3.878 then R2 4.022. Support is near S1 3.413 (already being tested/nearby) and S2 3.269. A breakdown toward/through 3.269 would reinforce the bearish trend. Pattern-based drift: Similar-pattern stats imply slightly negative near-term bias (about -3.15% over the next week) with only mild positive skew over the next month (+0.99%), consistent with “bearish now, maybe mean-revert later.”

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning vs Flow: Put open interest is relatively low versus calls (OI put/call 0.2), which can look structurally bullish. However, today’s trading flow is the opposite: put volume massively outweighs call volume (put-call volume ratio 6.19), implying traders are actively buying puts (bearish speculation or hedging) right now. Activity/Intensity: Today’s option volume is extremely elevated versus the 30-day average (~550% of average), signaling heightened short-term attention and likely risk-off positioning. Volatility: IV is low relative to its own history (IV percentile ~2.81; IV rank ~7.33), meaning options are “cheap” versus recent history. Low IV can be attractive for buyers of options, but combined with heavy put volume it more strongly suggests downside protection demand rather than bullish risk-taking. Net read: Near-term options sentiment leans bearish due to the put-heavy volume despite call-heavy open interest.

Technical Summary

Sell

Buy

Positive Catalysts

plus proximity to support (S1/S
can produce a short-term bounce.
on 2026-02-25 after hours could act as a catalyst if guidance/cash runway surprises positively.

Neutral/Negative Catalysts

with unusually high volume vs average, indicating strong near-term defensive/bearish sentiment.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 0 (no improvement in monetization). Profitability: Net income was -$50.33M, down ~24.56% YoY (loss widened). EPS: -0.45, down ~36.62% YoY (worse per-share loss). Growth trend takeaway: The quarter reflects continued pre-revenue biotech economics with worsening losses YoY, which typically pressures the stock unless the pipeline de-risks or financing outlook improves.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets have turned more cautious overall.

2025-11-18 JPMorgan: Downgraded to Underweight (no PT), citing challenging 12-month setup and risk in lead Danon program.
2025-11-18 BofA: Kept Buy but cut PT to $8 from $10 (cash position update).
2026-01-08 Morgan Stanley: Kept Equal Weight but cut PT to $5 from $7. Wall Street pros: Gene therapy portfolio in rare cardiovascular indications provides long-duration upside optionality; broader biotech backdrop could be supportive. Wall Street cons: Lead-program risk (Danon) and a difficult near-term catalyst setup; multiple PT cuts and a downgrade signal diminished confidence in near-term upside.

11 Analyst Rating

Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 8.63 USD with a low forecast of 5 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

4 Hold

1 Sell

Moderate Buy

Current: 3.000

Low

Averages

8.63

High

Current: 3.000

Low

Averages

8.63

High

Morgan Stanley

Equal Weight

downgrade

$7 -> $5

AI Analysis

2026-01-08

Reason

Morgan Stanley

Price Target

$7 -> $5

AI Analysis

2026-01-08

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Rocket Pharmaceuticals to $5 from $7 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

JPMorgan

Neutral -> Underweight

downgrade

2025-11-18

Reason

JPMorgan

Price Target

2025-11-18

downgrade

Neutral -> Underweight

Reason

JPMorgan downgraded Rocket Pharmaceuticals to Underweight from Neutral without a price target. The firm believes Rocket has an "interesting" gene therapy portfolio primarily aimed at rare, genetically driven heart conditions. While the shares as ascribing minimal pipeline credit, the setup is challenging for upside over the next 12 months, the analyst tells investors in a research note. JPMorgan sees risks with Rocket's lead program in Danon disease.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RCKT

Unlock Now

RCKT Should I Buy

RCKT Should I Buy

Should You Buy Rocket Pharmaceuticals Inc (RCKT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch